Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors.
about
Reply to Meshnick and Hastings et alOptimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast AsiaLongitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistanceThe spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study.The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia.Quantifying the pharmacology of antimalarial drug combination therapy.Malaria incidence in Myanmar 2005-2014: steady but fragile progress towards elimination.Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration.Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites.In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate.Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009-2013).Efficacy and safety of artesunate-mefloquine therapy for treating uncomplicated Plasmodium falciparum malaria: systematic review and meta-analysis.pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.Oxidative stress in malaria and artemisinin combination therapy: Pros and Cons.Combating multidrug-resistant Plasmodium falciparum malaria.Maximizing research study effectiveness in malaria elimination settings: a mixed methods study to capture the experiences of field-based staff.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Platinum(ii)-chloroquine complexes are antimalarial agents against blood and liver stages by impairing mitochondrial function.K13-propeller Alleles, Mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015.The threat of artemisinin resistant malaria in Southeast Asia.Artemisinin Resistance and the Blame Game.Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia.Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar.Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar.Role of K13 Mutations in Artemisinin-Based Combination Therapy.Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant Plasmodium falciparum In Vitro.Multidrug-resistant malaria and the impact of mass drug administration.Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.How to combat emerging artemisinin resistance: Lessons from "The Three Little Pigs".Drugs in Development for Malaria.Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar.Fitness Costs and the Rapid Spread of -C580Y Substitutions Conferring Artemisinin ResistanceSalivary Biomarker as a Proxy for Estimating Malaria Exposure on the Thailand-Myanmar BorderEfficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials
P2860
Q28595897-713D9FF5-FA32-4F42-8C41-E8D1ED4389D5Q28596975-2B63E9B3-2842-4DD4-8FC4-151610920338Q30044965-CDA34C64-9A17-44E7-9897-46E838276A27Q33607319-21EF13D9-7C8F-424A-BEE4-1A3DBA6A3A96Q33655603-D91F2E0F-43B2-42F9-A6F2-E6C17648C673Q33668137-83F2A5A4-EF34-491B-A96C-73791F051923Q37283299-64AA946A-568A-4A63-B487-1BAE0C004DB4Q37349461-F7EEF9CC-086B-4F5D-B199-8F48CE53AC83Q37402952-00EFC856-0509-4E64-A871-65E8C769FEF6Q37564232-32A7D4C9-4A64-4D8C-BC37-A7EE1957C10DQ37607795-77324E80-D70D-4505-9F23-2B807EE5CCE6Q38372219-2CA1413A-A818-4A22-B80B-993237302C1BQ39063353-4B504CAB-7B28-4F63-8C7B-DEA8E1F038FCQ39206934-6CF4D0E9-AD2C-48E7-B0FC-85F4874D18DAQ39280599-E3AC9670-D54D-42D4-ABA8-F498E8A87FC3Q39350422-AF219DE2-6398-4439-91FC-E8DB2E214FA6Q40053255-F8B96458-D613-459E-9FDD-04DDF9ED9D5CQ40106428-B83D369A-6ADF-4864-9710-DC6BEFA936A0Q41911875-B6DD4A5B-EF42-428F-85C7-3D8AB5ACED91Q41911890-31F5585F-F882-4D58-9CA4-3228AC829CCCQ42343414-DCDA1A42-3464-4B09-94C7-98E9556E36E0Q46673277-79F271A4-2722-45E7-8D4B-B33CD4CF5CACQ47100748-1AADB3A1-FF80-440B-97BF-446E09F6774CQ47108422-96B20DCE-6523-4E91-A277-0BA54AAD6EDCQ47120523-E51F0274-FE0B-46FB-B6C1-F2F49B902680Q47142321-BDEB9AC4-6634-47A6-B8B6-5ED69C24D1F1Q47973052-3076E4CF-71B5-4261-8317-990519857D4BQ52575118-2AFEFDD3-246F-461D-BF93-9B146EA44770Q52659761-1FD3B1AF-860F-4A26-A9A6-1C60A0A8B176Q53702249-B49AC28B-3CBC-4CD2-B138-7B196318C625Q54250760-DFA3A4E9-7C53-4C8A-9B89-BAB89AAE98F1Q55024751-2D618D4F-8A9B-479B-9AF9-5685FE81F7E9Q55054343-6E129D96-3453-4043-BFC3-5740A9B9914BQ55278895-0AE6C40D-CA48-4130-B80B-D89F82E983EBQ55711310-E0E1D1EF-2754-4E62-B8BE-0651DA985856Q56340109-0C144E0B-93BF-40D6-8A69-7C755A23D997Q56349493-4E3F977F-C7E0-4703-88E8-917C6BA86672Q56375478-F385B073-F1A1-4748-96A3-CE6F07E6C838
P2860
Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Declining Efficacy of Artemisi ...... e of Parasite Genetic Factors.
@en
Declining Efficacy of Artemisi ...... ria on the Thai-Myanmar Border
@nl
type
label
Declining Efficacy of Artemisi ...... e of Parasite Genetic Factors.
@en
Declining Efficacy of Artemisi ...... ria on the Thai-Myanmar Border
@nl
prefLabel
Declining Efficacy of Artemisi ...... e of Parasite Genetic Factors.
@en
Declining Efficacy of Artemisi ...... ria on the Thai-Myanmar Border
@nl
P2093
P2860
P50
P921
P356
P1476
Declining Efficacy of Artemisi ...... e of Parasite Genetic Factors.
@en
P2093
Atthanee Jeeyapant
Clare Ling
Elizabeth A Ashley
Jerzy Dziekan
Kamonchanok Konghahong
Marina McDew White
Stephane Proux
Tim J C Anderson
P2860
P304
P356
10.1093/CID/CIW388
P407
P50
P577
2016-06-16T00:00:00Z